BARD1 releases further positive results
BARD1 Life Sciences (ASX:BD1) has announced additional positive results from its BARD1-Ovarian test, indicating that the test returned 89% sensitivity and 82% specificity.
BD1 conducted the follow on OC-400V study to assess the effectiveness of its ovarian algorithm generated in the OC-400 study to detect ovarian cancer in an independent test of 82 new ovarian cancers and 27 previously tested healthy controls.
The results of the OC-400V study (as indicated below) are highly promising and showcase high accuracy for detection of ovarian cancer. The results are an improvement over those recorded in the OC-400 study of 82% sensitivity and 79% specificity in cross validation tests.
Thanks to the results, BD1 confirmed the promise of its algorithm and now believes that BARD1-Ovarian has the potential to become a key diagnostic aid for early detection of the cancer.
It should be noted, however, that this is an early stage company and success is no guarantee. Investors should seek professional financial advice before making an investment.
BD1 Executive Director and CSO Dr Irmgard Irminger-Finger spoke on the promising results, “This study provides further evidence of the robustness of the BARD1-Ovarian test.
“Upon transfer to a commercial platform, our ongoing product development efforts will focus on testing BARD1-Ovarian in larger sample sets and the addition of other immunogenic markers to our biomarker panel to further train the algorithm and increase its accuracy for early detection of ovarian cancer.”
BD1 CEO Leearne Hinch also informed the market that the company was in discussions with a number of contract laboratory organisations that could transfer its research essay to a commercial platform.
“BARD1 anticipates that transfer of our research assay to a commercial platform will enable more efficient development and commercialisation of our diagnostic pipeline for detection of lung, ovarian and other cancers,” she said.